Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 15/20 | 0.61 |
| ▸ | MAOA | P21397 | 2/20 | 0.41 |
| ▸ | MAOB | P27338 | 2/20 | 0.41 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6947390 | 0.84 | NOS2 (0.61) | NOS2MAOAMAOBCACNA2D1LMNA | |
| SCHEMBL6940392 | 0.84 | NOS2 (0.61) | NOS2MAOAMAOBLMNAGAA | |
| SCHEMBL6941212 | 0.77 | NOS2 (0.72) | NOS2MAOAMAOBMAPTTSHR | |
| SCHEMBL6937888 | 0.77 | NOS2 (0.72) | NOS2MAOAMAOBMAPTTSHR | |
| SCHEMBL6937632 | 0.76 | NOS2 (1.00) | NOS2MAOAMAOBMAPTTSHR | |
| SCHEMBL6940223 | 0.75 | NOS2 (0.75) | NOS2MAOAMAOBMAPTTSHR | |
| SCHEMBL6942303 | 0.75 | NOS2 (0.75) | NOS2MAOAMAOBMAPTTSHR | |
| SCHEMBL6945095 | 0.75 | NOS2 (0.59) | NOS2GAAMAPT | |
| SCHEMBL6946779 | 0.74 | NOS2 (0.61) | NOS2MAOAMAOB | |
| SCHEMBL6941331 | 0.74 | NOS2 (0.73) | NOS2MAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1268471-B1 | N-HETEROCYCLIC DERIVATIVES AS NOS INHIBITORS | SCHERING AG (DE) | 2003-10-15 | — | — | EP | disclosed |
| US-6525051-B2 | N-heterocyclic derivatives as NOS inhibitors | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-02-25 | — | — | US | disclosed |
| US-20020010190-A1 | N-heterocyclic derivatives as NOS inhibitors | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020010190-A1 | N-heterocyclic derivatives as NOS inhibitors | NOS1, NOS3, NOS2 | NOS2 3/4885MAOA 14/4885MAOB 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.